Direxion Daily Healthcare Bull 3X ETF

CURE

Capitalización de mercado USD 185 M

VANCOUVER, British Columbia - TheNewswire -  June 22 , 2026 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) announces that it has entered into a binding letter agreement dated June 22, 2026 with Glorious Success Limited. (“ GSL ”) whereby the Company will acquire all of the issued and outstanding securities of GSL (the “ Transaction ”). The Transaction will be a business combination completed by way of a share exchange, share purchase, amalgamation, arrangement, takeover bid, or other similar form of transaction.   Upon the successful completion of the proposed Transaction, it is anticipated that the Company will carry on the business of GSL (the “ Resulting Issuer ”). The Transaction constitutes a ‘reverse takeover' of the Company and is an arm's length transaction. Upon completion of the Transaction, it is expected that GSL will become a wholly owned subsidiary of the Company.

The Direxion Daily Healthcare Bull 3X ETF (CURE) has slipped in early 2026 as investors take profits after a strong performance in late 2025. The correction in healthcare stocks comes even as analysts envisage significant gains for CURE's ten largest holdings over the next 12 months. This dynamic may present an opportunity to rotate into CURE from the unlevereged XLV ETF, which tracks the same underlying index.

The first month of 2026 is already in the books. Which sector walked away with the top spot when it came to total returns?

Direxion Daily Healthcare Bull 3X Shares ETF has surged 83.5% since August 2025, reflecting bullish momentum in healthcare and pharma sectors. Reduced regulatory uncertainty, successful clinical trials, M&A activity, and prospects for 2026 rate cuts underpin the bullish thesis for CURE. CURE's leveraged structure amplifies both gains and losses, with significant time decay and risk, making it suitable only for tactical trading.

The Direxion Daily Healthcare Bull 3X Shares ETF has meaningfully outperformed the S&P 500 so far in 2025, benefiting from a recent shift in sentiment toward health care stocks. While CURE's underlying index is not as cheap as it was a few months ago, it still offers a roughly 19% forward P/E discount relative to the S&P 500. After strong recent returns, analysts project modest single-digit gains over the next 12 months for CURE's largest holdings.

Direxion continues to expand its single-stock ETF offerings for tactical traders. It has introduced five new single stock funds that add exposure to Oracle, Coinbase, Robinhood, and Intel.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

The healthcare sector is catching some flack, and rightfully so. For the three years ending October 15, the S&P Health Care Select Sector Index returned just 22.9%.

Amid rising concerns about stagflation, investors have continued to bid up the equities sector. As evidence, the benchmark S&P 500 sector is up over 13% year-to-date.

Large-cap momentum names have been pushing the healthcare sector aside. Investors have primarily been flocking to Magnificent Seven names benefiting from the artificial intelligence (AI) push.